Business Overview: Aligos Therapeutics, Inc. (NASDAQ: ALGS)

---

Executive Summary

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel, small-molecule and other therapeutics for the treatment of viral and liver diseases, most notably chronic hepatitis B (CHB), hepatitis delta virus (HDV), and metabolic dysfunction-associated liver diseases such as MASH (metabolic dysfunction-associated steatohepatitis). The company aims to develop finite, curative-intent treatment regimens rather than the lifelong suppressive therapies that dominate current hepatitis B treatment.

Headquartered in South San Francisco, California, Aligos has built a multi-program pipeline spanning several distinct antiviral mechanisms (including capsid assembly modulators and antisense/siRNA-adjacent approaches) as well as metabolic-liver-disease programs, reflecting a strategy of pursuing multiple scientifically differentiated shots on goal within related therapeutic areas.

---

1. Core Business Model & How They Work

Aligos discovers and advances novel small-molecule and nucleic-acid-based drug candidates through preclinical and clinical development, targeting large, underserved chronic viral and liver disease markets, with the goal of either commercializing approved therapies independently or partnering with larger pharmaceutical companies for late-stage development and commercialization.

[ Antiviral & Liver Disease Target Discovery ] ➡️ [ Preclinical & Clinical Development (CHB, HDV, MASH) ] ➡️ [ Regulatory Milestones ] ➡️ [ Potential Partnership or Independent Commercialization ]

Key Operational Drivers

1. Curative-Intent Hepatitis B Strategy: Unlike current standard-of-care nucleos(t)ide analogs, which require lifelong daily therapy for most chronic hepatitis B patients, Aligos is pursuing combination regimens intended to achieve finite-duration, functional cure outcomes — a highly sought-after but scientifically challenging goal in the field.
2. Diversified Multi-Program Pipeline: By advancing multiple distinct programs across hepatitis B, hepatitis delta, and MASH, Aligos spreads binary clinical-trial risk across several scientifically differentiated shots on goal rather than depending on a single candidate.
3. Large, Underserved Global Disease Burden: Chronic hepatitis B affects hundreds of millions of people globally, and hepatitis delta (which co-infects a subset of hepatitis B patients) represents one of the most severe forms of viral hepatitis with very limited treatment options — together representing a substantial commercial opportunity if a functional cure or significantly improved therapy is achieved.
4. Reliance on Capital Markets and Partnerships: As a clinical-stage company without approved products, Aligos depends on equity financing, non-dilutive grants, and potential pharmaceutical partnerships to fund its multi-program pipeline through late-stage development.

---

2. Business Segments

Aligos operates as a single integrated biopharmaceutical business organized around its pipeline programs:

• Chronic Hepatitis B (CHB) Programs: Multiple mechanistically distinct candidates aimed at achieving functional cure through finite combination therapy.
• Hepatitis Delta Virus (HDV) Programs: Therapeutics targeting HDV, a severe and difficult-to-treat co-infection affecting certain hepatitis B patients.
• MASH/Metabolic Liver Disease Programs: Candidates targeting metabolic dysfunction-associated steatohepatitis and related liver conditions, an area of intense industry-wide drug-development interest.

---

3. Product Portfolio & Revenue Contributors

---

4. Competitive Landscape

                    High Hepatitis B/Liver Disease Focus
                                 │
       Gilead Sciences ●         │           ● GSK (bepirovirsen)
                                 │
   Vir Biotechnology ●            │              ● Aligos Therapeutics (multi-mechanism pipeline)
                                 │
─────────────────────────────────┼─────────────────────────────────
   Large-Cap Diversified Antiviral│              Focused Hepatitis/Liver Disease Specialist
   Portfolio                     │
                                 │
                    Low Hepatitis B/Liver Disease Focus

Competitors by Domain

Chronic Hepatitis B / Functional Cure Research

• Key Competitors: Gilead Sciences, GSK (with its antisense candidate bepirovirsen), Vir Biotechnology, Arbutus Biopharma, and other biotechs pursuing hepatitis B curative combination approaches.
• Dynamics: The hepatitis B functional-cure field has attracted substantial industry investment given the large addressable patient population; Aligos competes based on the differentiation and combinability of its specific mechanisms (e.g., capsid assembly modulation) within multi-drug curative regimens likely to require combination therapy from multiple companies or licensed assets.

MASH/Metabolic Liver Disease

• Key Competitors: Madrigal Pharmaceuticals (with the first FDA-approved MASH therapy, Rezdiffra), Novo Nordisk, Eli Lilly, and numerous other biotechs pursuing MASH therapeutics.
• Dynamics: MASH has become an intensely competitive therapeutic area following the first approval in the category; Aligos is a smaller player in a field now populated by large-cap pharmaceutical companies with substantially greater resources.

---

5. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• Multi-mechanism pipeline diversification: Pursuing several scientifically distinct approaches within hepatitis B, HDV, and MASH reduces dependence on any single program's clinical success.
• Focus on an underserved curative-intent goal: A finite-duration functional cure for hepatitis B would represent a major clinical advance over current lifelong suppressive therapy, offering significant commercial upside if achieved.
• Patent-protected proprietary compounds: Aligos holds intellectual property around its novel small-molecule and nucleic-acid-based candidates.

Strategic Risks & Vulnerabilities

1. High clinical and scientific risk: Achieving a true functional cure for chronic hepatitis B has proven extremely difficult industry-wide, and any individual Aligos program faces meaningful failure risk.
   • Mitigation Strategy: Diversifying across multiple mechanisms and disease areas to spread binary trial risk.
2. Intensifying MASH competition from much larger players: The MASH field has rapidly become crowded with large-cap pharmaceutical competitors following Madrigal's approval.
   • Mitigation Strategy: Differentiating through specific mechanism and potential combination-therapy positioning rather than competing head-on for first-approval status.
3. Financing dependence as a clinical-stage company: Continued capital raises or partnerships are required to fund the company's multi-program pipeline through key value-inflection trial readouts.
   • Mitigation Strategy: Prioritizing capital allocation toward the most clinically and commercially promising programs.

---

6. Financial Overview & Performance Matrix

---

7. Summary Conclusion

Aligos Therapeutics has assembled a scientifically diversified pipeline targeting some of the largest and most underserved viral and metabolic liver disease markets globally, anchored by an ambitious strategy to develop finite-duration, curative-intent regimens for chronic hepatitis B alongside programs in hepatitis delta and MASH. This multi-program approach spreads clinical risk across several distinct scientific mechanisms rather than depending on a single binary outcome.

The company's long-term success depends on its ability to generate compelling clinical data supporting its curative-intent hepatitis B strategy, differentiate its MASH programs in an increasingly crowded field now populated by large-cap pharmaceutical competitors, and secure the financing or partnerships needed to advance its multi-program pipeline through the lengthy and expensive later stages of clinical development.